SHELTON, Conn., June 20, 2017 /PRNewswire/ --
NanoViricides, Inc., (NYSE MKT:
NNVC) (the "Company"), a pioneer in
developing anti-viral nanomedicine drugs, is pleased to announce
that its late-breaking abstract submission has been accepted for a
poster presentation at the 36th Annual Meeting of the American
Society of Virology (ASV). The ASV Meeting will be hosted and held
at the University of Wisconsin-Madison,
from June 24th to 28th, 2017
(https://extensionconferencecenters.uwex.edu/asv2017/).
Dr. Brian Friedrich, Senior
Virologist of the Company, will present the Company's work on the
evaluation of nanoviricides drug candidates for effectiveness
against the shingles virus (Varicella Zoster Virus, VZV, aka Human
HerpesVirus-3 or HHV-3). He will present data on both safety and
effectiveness of the nanoviricides drug candidates against VZV
infection in multiple different cell lines.
NanoViricides has recently announced that two of the
HerpeCide™ program drug candidates demonstrated complete
(almost 100%) inhibition of the varicella-zoster virus (VZV, aka
human herpesvirus 3 or HHV-3) at highest drug doses, whereas
acyclovir at the same drug dose exhibited only about 70% inhibition
of the virus. The nanoviricide drug candidates were almost five
times as effective as acyclovir in these assays. No cytotoxicity
was observed at any of the doses tested for the herpecide drug
candidates. Details of these studies will be presented in the
poster at the 2017 Annual Meeting of the ASV.
The NanoViricides poster, entitled "Novel Nanoviricides® Highly
Effective against Varicella Zoster Virus in Cell Culture" will be
presented in Poster Session II, open for viewing from 4pm to 6pm on Monday, June
26th, 2017.
About
NanoViricides:
NanoViricides,
Inc.
(www.nanoviricides.com)
is a development stage company that is creating special
purpose nanomaterials for antiviral therapy. The Company's novel
nanoviricide® class of drug candidates are designed to specifically
attack enveloped virus particles and to dismantle them. The Company
is developing drugs against a number of viral diseases including
H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and
genital Herpes, viral diseases of the eye including EKC and herpes
keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus,
among others.
This press release contains forward-looking
statements that reflect the Company's current expectation regarding
future events. Actual events could differ materially and
substantially from those projected herein and depend on a number of
factors. Certain statements in this release, and other written or
oral statements made by NanoViricides, Inc. are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. You
should not place undue reliance on forward-looking statements since
they involve known and unknown risks, uncertainties and other
factors that are, in some cases, beyond the Company's control and
which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. The Company
assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in
these forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission.. Although it is not possible to
predict or identify all such factors, they may include the
following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our
products.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-abstract-accepted-for-poster-presentation-at-the-2017-annual-meeting-of-american-society-of-virology-300476401.html
SOURCE NanoViricides, Inc.